Chen Huang

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn, Shukui Qin, Masafumi Ikeda et al. · New England Journal of Medicine · 2020 · 6.8K citations · Full text

Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial

Peter R. Galle, Richard S. Finn, Shukui Qin et al. · The Lancet Oncology · 2021 · 362 citations

Patient-reported Outcomes, Hepatology, Medicine +11

IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)

Ann‐Lii Cheng, S. Qin, Masafumi Ikeda et al. · Annals of Oncology · 2019 · 191 citations

Ph Iii Study, Hepatology, Medicine +10

Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis

Hongcheng Sun, Zhengjun Qiu, Jun Liu et al. · International Journal of Oncology · 2007 · 132 citations · Full text

Tumor Biology, Hypoxia-inducible Factor-1 Alpha, Oncology +15

Clinical significance of AXL kinase family in gastric cancer.

Chew-Wun Wu, Anna F.-Y. Li, Chin‐Wen Chi et al. · PubMed · 2002 · 107 citations